tert-Butanol → 7-{5-[1(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-3-pyridinyl}-4,5-dihydro[1,2,4]triazolo[4,3-a]quinoline

HRID 1521611Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1521611
Br[C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]1[CH:12]=[N:13][N:14]=[C:7]1[CH2:6][CH2:5]2.[CH:15]1([C:18]2[N:22]=[C:21]([C:23]3([C:26]4[CH:27]=[C:28](B(O)O)[CH:29]=[N:30][CH:31]=4)[CH2:25][CH2:24]3)[O:20][N:19]=2)[CH2:17][CH2:16]1.C(=O)([O-])[O-].[K+].[K+].C(O)(C)(C)C>CC(P(C(C)(C)C)C1C=CC(N(C)C)=CC=1)(C)C.CC(P(C(C)(C)C)C1C=CC(N(C)C)=CC=1)(C)C.Cl[Pd]Cl.O>[CH:15]1([C:18]2[N:22]=[C:21]([C:23]3([C:26]4[CH:27]=[C:28]([C:2]5[CH:3]=[C:4]6[C:9](=[CH:10][CH:11]=5)[N:8]5[CH:12]=[N:13][N:14]=[C:7]5[CH2:6][CH2:5]6)[CH:29]=[N:30][CH:31]=4)[CH2:25][CH2:24]3)[O:20][N:19]=2)[CH2:17][CH2:16]1

Komponenten

7

Edukt 4

HCID 6386tert-ButanolHCID 11430Potassium CarbonateHCID 21543699HCID 21543699, VerbindungHCID 89961641[5-[1-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-3-pyridinyl]boronic acid

Produkt 1

HCID 899615587-{5-[1(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-3-pyridinyl}-4,5-dihydro[1,2,4]triazolo[4,3-a]quinoline

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 11714597Bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)KatalysatorHCID 962WaterLösungsmittel

Reaktionsbedingungen

Temperatur
80 °C

Versuchsvorschrift

To a vial containing the title compound from Example 22 Step B (0.025 g, 0.100 mmol), the title compound from Example 72 Step C (0.027 g, 0.100 mmol), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (1.4 mg, 2.0 μmol), and potassium carbonate (0.041 g, 0.300 mmol) were added tert-butanol (1.1 mL) and water (0.14 mL). The vial was flushed with nitrogen, sealed tightly and heated to 80° C. overnight. The reaction solution was then cooled to room temperature and concentrated under reduced pressure. The resulting material was diluted with acetonitrile and purified by HPLC (C18 column, 10 to 100% acetonitrile/water, both 0.1% v/v trifluoroacetic acid). Fractions containing product were combined, aqueous 1 N HCl solution was added, and the resulting solution concentrated under reduced pressure to provide the title compound: LCMS m/z 397.02 [M+H]+; 1H NMR (500 MHz, CD3OD) δ 9.37 (s, 1H), 9.01 (s, 1H), 8.85 (s, 1H), 8.60 (s, 1H), 7.92-7.86 (m, 3H), 3.27-3.24 (m, 4H), 2.02-1.99 (m, 1H), 1.92-1.90 (m, 2H), 1.78-1.76 (m, 2H), 1.04-1.00 (m, 2H), 0.91-0.89 (m, 2H).

Aufarbeitung

  1. customThe vial was flushed with nitrogen
  2. customsealed tightly
  3. temperatureThe reaction solution was then cooled to room temperature
  4. concentrationconcentrated under reduced pressure
  5. additionThe resulting material was diluted with acetonitrile
  6. custompurified by HPLC (C18 column, 10 to 100% acetonitrile/water
  7. additionFractions containing product
  8. additionaqueous 1 N HCl solution was added
  9. concentrationthe resulting solution concentrated under reduced pressure

Quellen und Nachweise

ORD-Eintrag
ord-a0e80ca5049349ae897677587364ed1b
Quelldatensatz
uspto-grants-2015_07
Patentnummer
US09073929B2

Notizen zur Reaktion

Wird geladen…